(Q44375010)

English

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

scientific article published in April 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit (English)

1 reference

Europe PubMed Central

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

2 December 2017

Alessandra Ferrajoli

8

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

2 December 2017

5

object named as

Stefan Faderl

1 reference

Europe PubMed Central

2 December 2017

Srdan Verstovsek

7

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

2 December 2017

William G Wierda

9

object named as

William Wierda

1 reference

Europe PubMed Central

2 December 2017

Jorge Eduardo Cortes

3

object named as

Jorge Cortes

1 reference

Europe PubMed Central

2 December 2017

Guillermo Garcia-Manero

6

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

2 December 2017

Michael J. Keating

13

object named as

Michael J Keating

1 reference

Europe PubMed Central

2 December 2017

12

object named as

Maher Albitar

1 reference

Europe PubMed Central

2 December 2017

Apostolia Maria Tsimberidou

1

object named as

Apostolia M Tsimberidou

1 reference

Europe PubMed Central

2 December 2017

Francis J Giles

14

object named as

Francis J Giles

1 reference

Europe PubMed Central

2 December 2017

Susan M O'Brien

11

object named as

Susan M O'Brien

1 reference

Europe PubMed Central

2 December 2017

author name string

Deborah A Thomas

4

1 reference

Europe PubMed Central

2 December 2017

Yesid Alvarado

10

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

1 April 2003

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

97

1 reference

Europe PubMed Central

2 December 2017

1711-1720

1 reference

Europe PubMed Central

2 December 2017

7

1 reference

Europe PubMed Central

2 December 2017

Richter's syndrome: a report on 39 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Richter's syndrome in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with salvage regimens at M.D. Anderson Hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

The hyper-CVAD regimen in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal formulations of cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal encapsulated anthracyclines: new therapeutic horizons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP plus rituximab--balancing facts and opinion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging information on the use of rituximab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Invasive aspergillosis in 2002: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11238

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11238

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44375010&oldid=1858149192"